Drug discovery company MultiOmic Health and digital health start-up Mesh Bio will work together on an observational clinical study for patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease.
The partnership will provide access to data from patient populations in Asia that have historically been underrepresented in chronic metabolic disease studies.
Mesh Bio will utilise its network of healthcare provider customers to recruit patients for the study. MultiOmic will generate genomic, proteomic, metabolomic and potentially other omics data from anonymised body fluid samples. The companies will combine these with anonymised data from clinical and diagnostic tests for both companies to build a multiomics dataset and derive AI-based computational biology models.
MultiOmic Health and Mesh Bio will use to the study to progress their R&D programmes to develop precision therapeutic and diagnostic products aimed at patients with metabolic syndrome-related conditions. The companies will also jointly conduct collaborative projects to enhance patient stratification for other biopharma and medtech companies’ clinical-stage R&D programmes.
“Longitudinal multi-omics data combined with deep clinical phenotyping is essential to developing transformative therapeutics and diagnostics in chronic multi-factorial diseases,” said Angeli Möller, PhD, Vice-Chairperson and co-founder of the Alliance for Artificial Intelligence in Healthcare, the global advocacy organization for applying AI solutions to improve patient lives. “In contrast to most of the historical research for these diseases that has relied on Caucasian patients, this partnership will generate new and much needed insights specific to populations in Asia.”
“Mesh Bio is committed to driving precision clinical interventions in the management of chronic metabolic disease, in order to improve patient outcomes. Our vision is for holistic patient assessment, powered by analytics on fullstack biology,” said Andrew Wu, PhD, Co-Founder and CEO of Mesh. “We are delighted to partner with MultiOmic Health on this important study for patients in Asia. Their therapeutic development programs for metabolic disease intervention have deep synergies with Mesh Bio’s mission to develop digital care delivery solutions for these diseases.”
“This partnership gives us access to a population base in Asia exhibiting high and increasing prevalence of metabolic syndrome-related conditions,” said Robert Thong, mCo-Founder and CEO of MultiOmic. “We are delighted to collaborate with Mesh Bio as a like-minded and capable strategic partner working with healthcare providers that have many patients in our target chronic medical conditions. Our product development programmes and technical teams also complement each other.”